Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations
Go back to Dynavax Reports Third Quarter 2018 Financial Results, Progress on HEPLISAV-B Launch, and Updated SD-101 Data in Three Patient Populations| Dynavax Technologies Corporation (NASDAQ: DVAX) | Delayed: 15.50 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $15.50 | 52 Week High | $29.86 | |||
| Open | $15.50 | 52 Week Low | $3.20 | |||
| Day High | $15.50 | P/E | N/A | |||
| Day Low | $15.50 | EPS | $-0.41 | |||
| Volume | 25 | |||||
